The US FDA has issued a CRL for sNDA of Astellas Pharma’s IZERVAY, a treatment for geographic atrophy (GA) secondary to AMD.

Aclaris Therapeutics has secured an exclusive license from Biosion for the global rights to two new antibodies.

The FDA has released a draft of new guidance addressing common FAQs about the development of potential CGT treatments.

The upcoming clinical trial conferences will host talks on supply chain resilience, AI’s growing role and forging industry ...

Novartis has teamed up with Ratio Therapeutics in a $745m licensing and collaboration agreement to advance ...

ReCode is set to secure up to $15m in funding from the Cystic Fibrosis Foundation to enhance its gene correction research ...

Tirzepatide is a long-acting dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist ...

Novo Nordisk Pharmatech has entered an agreement with Signet Chemical Corporation for the distribution of its pharmaceutical range of ...